Recovering scientist turned early stage VC A biotech optimist fighting gravity

Leadership At All Levels In Biotech
January 23, 2019

This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC Biotech is an industry that calls for leaders. It requires people who are willing to take risks, conquer new science,

Leave a comment

Venture Volatility: 2018’s Banner Year Closed Cautiously
January 16, 2019

2018 was a gangbuster year for VC-funding into startups, reaching levels not seen since the height of the dot-com and genomics era. According to recent data from the NVCA/Pitchbook, VC across all sectors topped $130B invested across nearly 9000 deals

Leave a comment

The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference
January 14, 2019

Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry. For context, by JPM I don’t mean the actual J.P. Morgan Healthcare Conference at the Westin

Leave a comment

Biotech IPO Market: Closing The Books On 2018’s Crazy Year
January 3, 2019

2018 was a incredible boom year in the number of new biotech offerings, with 60 IPOs on US exchanges. But as we’re all painfully aware, after the overall biotech market ($XBI) touched its all-time high in August, the last third

Leave a comment

The World Cup of Conferences
December 7, 2018

This blog was written by Jason Gardner, CEO of Magenta Therapeutics and Liverpool soccer fan, as part of the From The Trenches feature of LifeSciVC. Nine presentations, three press releases, forty-two satellite meetings. One conference. Most biotech companies have that

Leave a comment

Generations: Talent Dispersion in Biotechnology
November 29, 2018

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. The evening of April 26, 2009, I walked from my hotel room to the nearest bar. The bar was

Leave a comment

Fleece vs Future: How Small Companies Can Help Build Biotech Talent
November 13, 2018

This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches features of LifeSciVC. A lot has been written about the biotech talent war in the Boston area including the availability of talent as

Leave a comment

How’s My Baby?
October 24, 2018

This blog was written by Samantha Truex, CEO of Quench Bio and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. In early September, I saw my two teenagers off to new destinations where they will live

Leave a comment

A New Translational Tool for Synaptopathies
October 19, 2018

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After decades of challenges in neuroscience research and development, there is new hope that we can design better clinical

Leave a comment

2018’s Biotech IPO Bonanza: View From the After Market
October 17, 2018

2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years. With lots of pundits

Leave a comment

Science2Startup 2019: Bringing Venture & Academia Together
October 15, 2018

After last year’s inaugural success, we’re excited for 2019’s Science2Startup conference in April 2019, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. Working with a steering committee comprised of Atlas,

Leave a comment

Targeting Aging Comes Of Age
October 11, 2018

This blog is written by Tom Hughes, CEO of Navitor Pharma, as part of the From The Trenches feature of LifeSciVC. We finally are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new

Leave a comment